Raphael Machado Castilhos

Prof. Dr. Raphael Machado Castilhos


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2022 in The Lancet Regional Health - Americas
Verified
Journal Article
Open access
WBWyllians Vendramini Borelli
Wyllians Vendramini Borelli
VLVanessa Bielefeldt Leotti
Vanessa Bielefeldt Leotti
MSMatheus Zschornack Strelow
Matheus Zschornack Strelow
MCMárcia Lorena Fagundes Chaves
Márcia Lorena Fagundes Chaves
RCRaphael Machado Castilhos
Raphael Machado Castilhos
Knowledge regarding the modifiable risk factors of dementia is fundamental to guide public health policy. We aimed to estimate the population attributable fraction of modifiable risk factors of dementia among adults from a nationwide epidemiological study. We used the public database of the Brazilian Longitudinal Study of Aging (ELSI-Brazil) to calculate the Population Attributable Fraction (PAF) for ten risk factors, including education level, hearing loss, hypertension, alcohol consumption, obesity, active smoking, depression, social isolation, physical inactivity, and diabetes. PAF was estimated for this sample after accounting for the communality of each risk factor. The ten preventable risk factors for dementia accounted for 50·5% of the Population Attributable Fraction in Brazil. Hearing loss (14·2%), physical inactivity (11·2%), and hypertension (10·4%) accounted for the highest PAF among all the risk factors. Considerable variation in the relative contribution of the different risk factors was found in different regions. This study might provide an opportunity to change the impact of dementia in Brazil. By targeting modifiable risk factors of dementia, the health of individuals in Brazil might be considerably improved. This study did not receive any funding.

10 September 2024 in Neurology
Verified
Journal Article
Closed access
ABAndrei Bieger
Andrei Bieger
WBWagner S. Brum
Wagner S. Brum
WBWyllians V. Borelli
Wyllians V. Borelli
JTJoseph Therriault
Joseph Therriault
MBMarco A. De Bastiani
Marco A. De Bastiani
FIFor The Alzheimer'S Disease Neuroimaging Initiative
For The Alzheimer'S Disease Neuroimaging Initiative
Updates in Alzheimer disease (AD) diagnostic guidelines by the National Institute on Aging-Alzheimer's Association (NIA-AA) and the International Working Group (IWG) over the past 11 years may affect clinical diagnoses. We assessed how these guidelines affect clinical AD diagnosis in a cohort of cognitively unimpaired (CU) and cognitively impaired (CI) individuals. We applied clinical and biomarker data in algorithms to classify individuals from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort according to the following diagnostic guidelines for AD: 2011 NIA-AA, 2016 IWG-2, 2018 NIA-AA, and 2021 IWG-3, assigning the following generic diagnostic labels: (1) not AD (nAD), (2) increased risk of developing AD (irAD), and (3) AD. Diagnostic labels were compared according to their frequency, convergence across guidelines, biomarker profiles, and prognostic value. We also evaluated the diagnostic discordance among the criteria. A total of 1,195 individuals (mean age 73.2 ± 7.2 years, mean education 16.1 ± 2.7, 44.0% female) presented different repartitions of diagnostic labels according to the 2011 NIA-AA (nAD = 37.8%, irAD = 23.0%, AD = 39.2%), 2016 IWG-2 (nAD = 37.7%, irAD = 28.7%, AD = 33.6%), 2018 NIA-AA (nAD = 40.7%, irAD = 9.3%, AD = 50.0%), and 2021 IWG-3 (nAD = 51.2%, irAD = 8.4%, AD = 48.3%) frameworks. Discordant diagnoses across all guidelines were found in 512 participants (42.8%) (138 [91.4%] occurring in only β-amyloid [CU 65.4%, CI 34.6%] and 191 [78.6%] in only tau-positive [CU 71.7%, CI 28.3%] individuals). Differences in predicting cognitive impairment between nAD and irAD groups were observed with the 2011 NIA-AA (hazard ratio [HR] 2.21, 95% CI 1.34-3.65, p = 0.002), 2016 IWG-2 (HR 2.81, 95% CI 1.59-4.96, p < 0.000), and 2021 IWG-3 (HR 3.61, 95% CI 2.09-6.23, p < 0.000), but not with 2018 NIA-AA (HR 1.69, 95% CI 0.87-3.28, p = 0.115). Over 42% of the studied population presented discordant diagnoses when using the different examined AD criteria, mostly in individuals with a single positive biomarker. Except for 2018 NIA-AA, all guidelines identified asymptomatic individuals at risk of cognitive impairment. Our findings highlight important differences between the guidelines, emphasizing the necessity for updated criteria with enhanced staging metrics, considering clinical, research, therapeutic, and trial design aspects.

14 November 2022 in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Verified
Journal Article
Open access
WBWyllians Vendramini Borelli
Wyllians Vendramini Borelli
EZEduardo R. Zimmer
Eduardo R. Zimmer
ABAndrei Bieger
Andrei Bieger
BCBruna Coelho
Bruna Coelho
TPTharick A. Pascoal
Tharick A. Pascoal
RCRaphael Machado Castilhos
Raphael Machado Castilhos
Introduction: Subjective cognitive decline (SCD) may be an early symptom of Alzheimer's disease. We aimed to estimate the prevalence of SCD in Brazil and its association with dementia modifiable risk factors.Methods: We used data of 8138 participants from the Brazilian Longitudinal Study of Aging (ELSI‐Brazil), a population‐based study that included clinical and demographic variables of individuals across the country. We calculated the prevalence of SCD and its association with dementia modifiable risk factors.Results: We found that the prevalence of SCD in Brazil was 29.21% (28.22%–30.21%), varying according to region, sex, and age. SCD was strongly associated with hearing loss, low education, psychological distress, Brown/Pardo and Black races.Discussion: The prevalence of SCD in Brazil is higher than in high‐income countries. Brown/Black races and dementia modifiable risk factors were associated with SCD. Public strategies that target SCD may help mitigate the incidence of dementia.

1 November 2015 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
JSJonas Alex Morales Saute
Jonas Alex Morales Saute
CRCarlos R. M. Rieder
Carlos R. M. Rieder
RCRaphael Machado Castilhos
Raphael Machado Castilhos
TMThais Lampert Monte
Thais Lampert Monte
ASArtur F. Schumacher-Schuh
Artur F. Schumacher-Schuh
LJLaura Bannach Jardim
Laura Bannach Jardim

28 November 2023 in European Journal of Neurology
Verified
Journal Article
Open access
NFNaomi Vidal Ferreira
Naomi Vidal Ferreira
NGNatalia Gomes Gonçalves
Natalia Gomes Gonçalves
CSClaudia Szlejf
Claudia Szlejf
AGAlessandra C Goulart
Alessandra C Goulart
ISItamar Santos
Itamar Santos
CSClaudia Suemoto
Claudia Suemoto
Background: Life's Simple 7, a lifestyle and cardiovascular index associated with cognition, has been updated to Life's Essential 8 (LE8) to include sleep. LE8 has been related to cardiovascular outcomes but its association with cognition is unclear.Methods: In this longitudinal analysis of the Brazilian Longitudinal Study of Adult Health (ELSA‐Brasil), LE8 score was based on health behaviors (diet, physical activity, nicotine exposure, and sleep health) as well as health‐related factors (body mass index, blood lipids, blood glucose, and blood pressure). Cognition was assessed in three waves, 4 years apart, using the Consortium to Establish a Registry for Alzheimer's Disease – Word List, semantic and phonemic verbal fluency, the Trail‐Making Test B (TMT‐B), and a global composite score. We used linear mixed‐model analysis, inverse probability weighting, and interaction analysis.Results: At baseline, the mean age of the study cohort was 51.4 ± 8.9 years, 56% were women, and 53% were White. Higher baseline LE8 scores were associated with slower decline in global cognition (β = 0.001, 95% confidence interval [CI] 0.001, 0.002; p < 0.001), memory (β = 0.001, 95% CI 0.000, 0.002; p = 0.013), verbal fluency (β = 0.001, 95% CI 0.000, 0.002; p = 0.003), and TMT‐B (β = 0.004, 95% CI 0.003, 0.005; p < 0.001). This association was mainly driven by LE8 health factors, particularly blood glucose and blood pressure. Age, sex, and race were modifiers of the association between LE8 and global cognitive decline (p < 0.001), suggesting it was more pronounced in older, male, and Black participants.Conclusions: Higher baseline LE8 scores were associated with slower global and domain‐specific cognitive decline during 8 years of follow‐up, mainly due to health factors such as blood glucose and blood pressure. Sociodemographic factors were modifiers of this association.

1 January 2024 in Dementia & Neuropsychologia
Verified
Journal Article
Open access
PDF file
BBBreno José Alencar Pires Barbosa
Breno José Alencar Pires Barbosa
ERElisa de Paula França Resende
Elisa de Paula França Resende
RCRaphael Machado Castilhos
Raphael Machado Castilhos
WBWyllians Vendramini Borelli
Wyllians Vendramini Borelli
NFNorberto Anízio Ferreira Frota
Norberto Anízio Ferreira Frota
ANAdalberto Studart Neto
Adalberto Studart Neto
Novel therapies for Alzheimer’s disease, particularly anti-amyloid drugs like lecanemab and donanemab, have shown modest clinical benefits but also significant risks. The present paper highlights the challenges of access to diagnosis, cost-effectiveness, safety, and the need for more representation of diverse populations in clinical trials. Recommendations include careful patient selection, risk-benefit analysis, and the importance of proven amyloid pathology for treatment. Future work involves further research on anti-amyloid therapies in Brazil and the development of more effective treatments for Alzheimer’s disease.